San Diego (CA) - USA
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that clinical data for lirilumab and IPH4102 were presented in two posters at the American Society of Hematology’s (ASH) 2016 Annual Meeting (December 3-6, 2016), San Diego, CA, U.S.:
Poster 1826 entitled “First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results” was presented by Prof. Y. Kim from the Stanford Cancer Institute and investigator of the study. IPH4102 is Innate Pharma’s wholly-owned first-in-class anti-KIR3DL2 antibody.
Poster 1641 entitled “Phase IB/II Study of Lirilumab in Combination with Azacytidine in Patients with Relapsed Acute Myeloid Leukemia” was presented by Dr N. Daver from the Department of Leukemia at the MD Anderson Cancer Center.